Dr. Reddy’s Laboratories Ltd. on Tuesday announced the launch of a novel gastrointestinal therapy in India, betting on a next-generation acid blocker to strengthen its branded portfolio in a market where nearly four in 10 people suffer from acid-related disorders.
The Hyderabad-based drugmaker launched Tegoprazan, a potassium-competitive acid blocker (PCAB), under the brand name PCAB, according to a company statement Tuesday. The drug is indicated for conditions such as erosive and non-erosive gastroesophageal reflux disease (GERD) and gastric ulcers, offering faster onset and longer pH control than conventional treatments, the company said.
The rollout follows Dr. Reddy’s exclusive licensing deal with South Korea’s HK inno.N Corp. in 2022 to commercialize Tegoprazan in India and select emerging markets. The molecule is already approved in 21 countries, including South Korea and China, and has completed Phase III trials in the U.S.
“We are happy to launch Tegoprazan in India, reinforcing our commitment to innovation in gastrointestinal disease treatment — a key focus area for us,” said M.V. Ramana, chief executive officer for branded markets at Dr. Reddy’s.
“Our partnership with HK inno.N brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management,” he added.
Acid peptic disorders affect about 38% of India’s population, underscoring the commercial potential for new therapies. In a multinational clinical trial conducted by Dr. Reddy’s across India, South Africa and Russia, 99% of GERD patients on Tegoprazan achieved endoscopic healing by Week 8, the company said.
HK inno.N CEO Dal-Won Kwak said the launch marks a milestone for the PCAB class in India. “We hope Tegoprazan will establish itself as a leading innovative therapy and contribute meaningfully to the improvement of gastrointestinal care,” he said.
The introduction of Tegoprazan adds to Dr. Reddy’s established gastrointestinal portfolio, which includes brands such as Omez, Razo and Vono. Dr Reddy's has been expanding its branded generics and specialty offerings in India and emerging markets to offset pricing pressure in the US generics segment.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
